Insmed’s Amikacin Faces US FDA Questions On Surrogate Endpoint, Target Population

 
• By Sue Sutter
  
Mycrobacteria_686575531_1200.jpg
Insmed seeks approval for adults with nontuberculous mycobacterial lung disease caused by Mycobaterim avium complex.

More from US FDA Performance Tracker

More from Regulatory Trackers